-
Statins and Venous Thromboembolic Disease – Where are we Now? Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2024-03-05 Pavel Poredoš, Debabrata Mukherjee, Aleš Blinc
: Classical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation
-
Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2024-02-07 Ozge Telci Caklili, Manfredi Rizzo, Mustafa Cesur
: Statins play a significant role in the prevention of cardiovascular (CV) diseases (CVDs); however, non-adherence with statin treatment or statin intolerance (mainly attributed to muscleassociated side effects) is not uncommon. New agents such as bempedoic acid (BA) can provide more treatment options. BA is administered orally, once daily, at a dose of 180 mg in current clinical practice. It can decrease
-
Effect of Intermittent Fasting on Lipid Profile, Anthropometric and Hepatic Markers in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2024-02-04 María Fernanda Castillo, Daniela Salgado-Canales, Marco Arrese, Francisco Barrera, Dimitri P Mikhailidis
Background: The first-line treatment for non-alcoholic fatty liver disease (NAFLD) is lifestyle modification; this should accompany any pharmacological intervention. Intermittent fasting (IF) has shown benefits over metabolic and cardiovascular parameters. Non-religious IF includes Time-Restricted Feeding (TRF), Alternate-Day Fasting (ADF), and 5:2 IF interventions. Objective: To evaluate the effects
-
Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2024-01-29 Mais N. Alqasrawi, Zeina N. Al-Mahayri, Hiba Alblooshi, Habiba Alsafar, Bassam R. Ali
Background: Statins are the most prescribed lipid-lowering drugs worldwide. The associated adverse events, especially muscle symptoms, have been frequently reported despite their perceived safety. Three pharmacogenes, the solute carrier organic anion transporter family member 1B1 (SLCO1B1), ATP-binding cassette subfamily G member 2 (ABCG2), and cytochrome P450 9C9 (CYP2C9) are suggested as safety biomarkers
-
Cytoplasmic Polyadenylation Element Binding Protein 1 and Atherosclerosis: Prospective Target and New Insights Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2024-01-29 Jing Zhou, Chao-Ke Tang
: The ribonucleic acid (RNA)-binding protein Cytoplasmic Polyadenylation Element Binding Protein 1 (CPEB1), a key member of the CPEB family, is essential in controlling gene expression involved in both healthy physiological and pathological processes. CPEB1 can bind to the 3'- untranslated regions (UTR) of substrate messenger ribonucleic acid (mRNA) and regulate its translation. There is increasing
-
Hyperparathyroidism and Peripheral Arterial Disease Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2024-01-29 Pier Luigi Antignani, Mateja K Jezovnik, Ales Blinc, Dimitri P. Mikhailidis, Panagiotis Anagnostis, Gerit-Holger Schernthaner, Mojca Jensterle, Katica Bajuk Studen, Miso Sabovic, Pavel Poredos
: Primary hyperparathyroidism (PHPT) is presented in various forms, including classic PHPT, characterised by increased parathyroid hormone (PTH) secretion, normohormonal PHPT, and normocalcaemic PHPT. Secondary hyperparathyroidism is characterised by increased PTH secretion triggered by factors such as vitamin D deficiency and kidney failure. This review aims to discuss the involvement of hyperparathyroidism
-
Sedation with Ketamine-Propofol in Patients Undergoing Transcatheter Aortic Valve Implantation: A Comparative Retrospective Study on General Anesthesia Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2024-01-29 Nurdan Yilmaz, Yasar Gokhan Gul, Murat Ugurlucan
Background: Transcatheter aortic valve implantation (TAVI) is used for patients with severe aortic stenosis who are at high risk for surgery. Since these patients are elderly and have comorbidities, their management is of great importance. Objectives: This retrospective study compares two anesthesia techniques during TAVI: sedation (ketamine and propofol) and general anesthesia. Methods: Patients with
-
Cardiac Radiofrequency Ablation Exacerbates Myocardial Injury through Pro-Inflammatory Response and Pro-Oxidative Stress in Elderly Patients with Persistent Atrial Fibrillation Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2024-01-12 Xia Li, Wenhang Zhou, Dianxuan Guo, Youdong Hu, Hualan Zhou, Ying Chen
Background: There is a need to assess myocardial damage after radiofrequency ablation of the pulmonary veins (PV) for persistent atrial fibrillation (PAF) in elderly patients. Objective: To evaluate oxidative stress, inflammatory response and myocardial damage in elderly patients with PAF after radiofrequency ablation of the PV. Methods: High-sensitivity troponin T (hsTnT), malondialdehyde-modified
-
Dapagliflozin Alleviates Myocardial Ischaemia Reperfusion Injury by Activating Mitophagy via the AMPK-PINK1/Parkin Signalling Pathway Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-12-23 Wei Zuo, Liang Wang, Ran Tian, Lun Wang, Yifan Liu, Hao Qian, Xinglin Yang, Zhenyu Liu
Introduction:: Myocardial ischaemia reperfusion injury (MIRI) determines infarct size and long-term outcomes after acute myocardial infarction (AMI). Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, alleviates MIRI in animal models. Method:: We investigated the potential mechanisms underlying the cardioprotective effect of dapagliflozin against MIRI, focusing on mitochondrial injury and mitophagy
-
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-12-23 Debabrata Mukherjee, Steven E Nissen
Background: Lipoprotein (a) [Lp(a)] is a molecule that induces inflammation of the blood vessels, atherogenesis, valvular calcification, and thrombosis. Methods: We review the available evidence that suggests that high Lp(a) levels are associated with a persisting risk for atherosclerotic cardiovascular diseases despite optimization of established risk factors, including low-density lipoprotein cholesterol
-
Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-12-20 Renata Trabach Santos, Maria Eduarda de Sá Freire Onofre, Dayene de Assis Fernandes Caldeira, Adriane Bello Klein, Patricia Rieken Macedo Rocco, Fernanda Ferreira Cruz, Pedro Leme Silva
: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by an imbalance between vasoactive mediators, which causes vascular remodeling, increased pulmonary vascular resistance, and right ventricular overload, ultimately leading to heart failure and death. A metabolic theory has been suggested to explain the pathophysiology of PAH whereby abnormalities in mitochondrial biogenesis
-
Proposal of a Modified Classification of Hypertensive Crises: Urgency, Impending Emergency, and Emergency Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-12-15 Goran Koracevic, Milovan Stojanovic, Marija Zdravkovic, Dragan Lovic, Dragan Simic, Katarina Mladenovic
: Systemic arterial hypertension (HTN) is the main cause of morbidity and mortality, and HTN crises contribute significantly to an unfavourable clinical course. For decades, HTN crises have been dichotomized into hypertensive emergency (HTN-E) and hypertensive urgency (HTN-U). The main difference between the two is the presence of acute hypertension-mediated organ damage (HMOD) – if HMOD is present
-
QTc Prolongation to Predict Mortality in Patients Admitted with COVID- 19 Infection: An Observational Study Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-12-11 Andrea Sartorio, Giulia Burrei, Luca Cristin, Mirko Zoncapè, Michele Carlin, Enrico Tadiello, Pietro Minuz, Andrea Dalbeni, Simone Romano
Background:: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes Coronavirus disease 2019 (COVID-19), characterized by pulmonary infection ranging from asymptomatic forms to respiratory insufficiency and death. Evidence of cardiac involvement in COVID-19 is increasing, and systemic inflammation or direct heart damage by SARS-CoV-2 can prolong the corrected QT interval (QTc). Methods::
-
Strategies to Minimize Access Site-related Complications in Patients Undergoing Transfemoral Artery Procedures with Large-bore Devices Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-12-11 Sabato Sorrentino, Assunta Di Costanzo, Nadia Salerno, Alessandro Caracciolo, Federica Bruno, Alessandra Panarello, Antonio Bellantoni, Annalisa Mongiardo, Ciro Indolfi
: Large bore accesses refer to accesses with a diameter of 10 French or greater and are necessary for various medical devices, including those used in transcatheter aortic valve replacement, endovascular aneurysm repair stent-grafts, and percutaneous mechanical support devices. Notably, the utilization of these devices via femoral access is steadily increasing due to advancements in technology and
-
Endocrine Disorders and Peripheral Arterial Disease – A Series of Reviews Cushing Syndrome-Cortisol Excess Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-12-01 Poredos P., Schernthaner GH, Blinc A, Mikhailidis DP, Jensterle M, Anagnostis P, Antignani PL, Bajuk Studen K, Šabović M, Ježovnik MK
: Cushing syndrome (CS), characterised by endogenous or exogenous glucocorticoid hormone excess, is associated with several systemic complications, including impaired glucose metabolism, which often becomes clinically manifest as diabetes mellitus (DM). In addition, CS can harm the arterial wall because of hyperglycaemia, dyslipidaemia, hepatic steatosis, and central obesity. These metabolic disorders
-
Diagnostic Value of Serum Galectin-3 Binding Protein Level in Patients with Pulmonary Arterial Hypertension Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-12-01 Mingfei Li, Wenzhi Pan, Dan Tian, Dandan Chen, Xiaochun Zhang, Yuan Zhang, Shasha Chen, Daxin Zhou, Junbo Ge
Background: Pulmonary arterial hypertension (PAH) still lacks effective biomarkers to assist in its diagnosis and prognosis. Galectin-3 binding protein (Gal-3BP) plays a role in immune and inflammatory diseases. Objective: This study aimed to evaluate Gal-3BP as a prognostic and predictive factor in patients with PAH. Methods: From January 2017 to December 2019, we enrolled 167 consecutive PAH patients
-
Study of Osteopontin as a Marker of Arteriovenous Shunt Stenosis in Hemodialysis Patients Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-11-30 Marwa R. Elbarbary, Laila A. Ahmed, Doaa A. El-Adl, Alshimaa A. Ezzat, Sherif A. Nassib
Introduction: Although arteriovenous fistula (AVF) is the recommended access for hemodialysis (HD), it carries a high risk for stenosis. Since osteopontin (OPN) is implicated in the process of vascular calcification in HD patients, OPN may be a marker for AVF stenosis. The present study evaluated OPN as a potential marker of AVF stenosis in HD patients. Methods: Diagnosing a stenotic lesion was made
-
Evaluation of Clinical, Echocardiographic, and Therapeutic Characteristics, and Prognostic Outcomes of Coexisting Heart Failure among Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-11-30 Nasr Alrabadi, Mohammed Al-Nusair, Farah K. El-zubi, Mais Tashtoush, Osama Alzoubi, Sa’ed Khamis, Majd M. Masadeh, Karem H. Alzoubi, Mohammed Al-Hiari, Ayman Hammoudeh
Background: Atrial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in clinical practice. Heart failure (HF) can occur concurrently with AF. Aim: We compared different demographic, clinical, and echocardiographic characteristics between patients with AF+HF and patients with AF only. Furthermore, we explored whether concurrent HF independently predicts several outcomes (all-cause
-
Beta-blockers in Hypertensive Left Ventricular Hypertrophy and Atrial Fibrillation Prevention Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-11-27 Goran Koracevic, Sladjana Micic, Milovan Stojanovic, Marija Zdravkovic, Dragan Simic, Tomislav Kostic, Vesna Atanaskovic, Ružica Janković-Tomašević
Background: Hypertensive left ventricular hypertrophy (HTN LVH) is a key risk factor for atrial fibrillation (AF). Objective: To evaluate the possible role of beta-blockers (BBs) in addition to a renin-angiotensinaldosterone system (RAAS) blocker in AF prevention in patients with HTN LVH. Methods: We performed a PubMed, Elsevier, SAGE, Oxford, and Google Scholar search with the search items ‘beta blocker
-
The Role of TRIM Proteins in Vascular Disease Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-11-22 Xinxin Chen, Xiaolong Chen
There are more than 80 different tripartite motifs (TRIM) proteins within the E3 ubiquitin ligase subfamily, including proteins that regulate intracellular signaling, apoptosis, autophagy, proliferation, inflammation, and immunity through the ubiquitination of target proteins. Studies conducted in recent years have unraveled the importance of TRIM proteins in the pathophysiology of vascular diseases
-
Lanthanum Hydroxide and Chronic Kidney Disease Mineral and Bone Disorder: A Rat Model Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-11-14 Chao Gu, Ting Zhang, Yuan Gao, Xiaojia Li, Xiaorong Yuan, Qiwen Wang, Hong Liu, Ruilan Han, Gang LI
Objective: To investigate the pharmacological effects and molecular mechanisms of lanthanum hydroxide(LH) on ectopic mineralization of soft tissue and abnormal bone in rats with acute kidney injury(AKI). Methods: Wistar rats were modeled by 5/6 nephrectomy. After the operation, the rats were divided into different groups, the biochemical indexes of serum collected at different times. Lanthanum hydroxide
-
Growth Hormone, Atherosclerosis and Peripheral Arterial Disease: Exploring the Spectrum from Acromegaly to Growth Hormone Deficiency Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-11-13 Herman R, Janez A, Mikhailidis DP, Poredos P, Blinc A, Sabovic M, Bajuk Studen K, Schernthaner GH, Anagnostis P, Antignani PL, Jensterle M
Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are increasingly recognised for their role in cardiovascular (CV) physiology. The GH-IGF-1 axis plays an essential role in the development of the CV system as well as in the complex molecular network that regulates cardiac and endothelial structure and function. A considerable correlation between GH levels and CV mortality exists even among
-
Thyroid Disorders and Peripheral Arterial Disease Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-11-10 Katica Bajuk Studen, Simona Gaberscek, Katja Zaletel, Ales Blinc, Miso Sabovic, Gerit-Holger Schernthaner, Panagiotis Anagnostis, Pier Luigi Antignani, Mojca Jensterle, Dimitri P Mikhailidis, Pavel Poredos
Hypothyroidism and hyperthyroidism, both overt and subclinical, are associated with increased risk of cardiovascular morbidity and mortality. The association between thyroid-stimulating hormone levels and cardiovascular risk has been demonstrated in large epidemiological studies and meta-analyses and is now considered a U-shaped curve. Several pathophysiological mechanisms linking thyroid and cardiovascular
-
A Nutraceutical Compound Containing a Low Dose of Monacolin K, Polymethoxyflavones, Phenolic Acids, Flavonoids, and Hydroxytyrosol Improves HDL Functionality Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-10-26 Carlo Cervellati, Alessandro Trentini, Valentina Rosta, Giovanni Zuliani, Francesco Vieceli Dalla Sega, Francesca Fortini, Paola Rizzo, Paolo Cimaglia, Gianluca Campo
Background: In earlier studies, it has been observed that 8-week treatment with a novel nutraceutical compound (NC) containing low monacolin K dose, polymethoxyflavones, phenolic acids, flavonoids, and hydroxytyrosol improves lipid profile and endothelial function and reduces the level of oxidized low-density lipoprotein (oxLDL). We hypothesize that this effect might be, at least in part, explained
-
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-10-18 Xiuying Tang, Runjun Li
Objective: This study evaluated the efficacy and safety of early vs. late tirofiban administration in the treatment of patients with acute ST-elevation myocardial infarction (STEMI) and diabetes mellitus (DM) undergoing primary percutaneous coronary intervention (pPCI). Methods: 120 patients with STEMI and DM treated with pPCI were randomly divided into an observation group (n=60) and a control group
-
Role of Vitamins in Cardiovascular Health: Know Your Facts - Part 1 Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-10-17 Antonis A. Manolis, Theodora Manolis, Helen Melita, Antonis S. Manolis
Cardiovascular (CV) disease (CVD) is a major cause of morbidity and mortality world-wide, thus it is important to adopt preventive interventions. Observational data demonstrating CV benefits of vitamin supplements, advanced by self-proclaimed experts have resulted in ~50% of Americans reporting the use of multivitamins for health promotion; this practice has led to a multi-billion-dollar business of
-
Role of Vitamins in Cardiovascular Health: Know Your Facts-Part 2 Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-10-17 Antonis A. Manolis, Theodora A. Manolis, Helen Melita, Antonis S. Manolis
Cardiovascular disease (CVD) is a major cause of morbidity/mortality world-wide, hence preventive interventions are crucial. Observational data showing beneficial CV effects of vitamin supplements, promoted by self-proclaimed experts, have led to ~50% of Americans using multivitamins; this practice has culminated into a multi-billion-dollar business. However, robust evidence is lacking, and certain
-
Testosterone and Peripheral Arterial Disease Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-09-27 Aleš Blinc, Gerit Holger Schernthaner, Pavel Poredoš, Panagiotis Anagnostis, Mojca Jensterle, Katica Bajuk Studen, Pier Luigi Antignani, Dimitri P. Mikhailidis, Mišo Šabović
Testosterone levels in men begin declining in the early years of adulthood, with a 1-2% reduction/year. Low testosterone levels in men are associated with obesity, metabolic syndrome, diabetes mellitus, dyslipidaemia, hypertension and increased cardiovascular mortality. However, observational studies of testosterone levels in males and their relationship with peripheral arterial disease (PAD) have
-
The Effect of Menopause and Menopausal Hormone Therapy on the Risk of Peripheral Artery Disease Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-09-27 Panagiotis Anagnostis, Dimitri P. Mikhailidis, Ales Blinc, Mojca Jensterle, Mateja K. Ježovnik, Gerit-Holger Schernthaner, Pier Luigi Antignani, Katica Bajuk Studen, Miso Šabović, Pavel Poredos
Peripheral artery disease (PAD), defined as lower extremity arterial disease, constitutes an underestimated aspect of the menopause-associated risk of atherosclerotic cardiovascular disease (ASCVD). Accumulation of ASCVD risk factors, such as atherogenic dyslipidaemia, diabetes, and arterial hypertension, after the transition to menopause may contribute to atherosclerotic plaque formation in peripheral
-
Analysis of the Research Hotspot of Exosomes in Cardiovascular Disease: A Bibliometric-based Literature Review Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-09-27 Jing Cui, Yiwen Li, Mengmeng Zhu, Yanfei Liu, Yue Liu
Objective: To investigate the current status and development trend of research on exosomes in cardiovascular disease (CVD) using bibliometric analysis and to elucidate trending research topics. Methods: Research articles on exosomes in CVD published up to April 2022 were retrieved from the Web of Science database. Data were organized using Microsoft Office Excel 2019. CiteSpace 6.1 and VOSviewer 1
-
Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-09-27 Andrej Janez, Rok Herman, Pavel Poredos, Dimitri P. Mikhailidis, Ales Blinc, Miso Sabovic, Katica Bajuk Studen, Mateja Kaja Jezovnik, Gerit-Holger Schernthaner, Panagiotis Anagnostis, Pier Luigi Antignani, Mojca Jensterle
Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder in women of reproductive age. It presents with gynaecologic, metabolic, and psychologic manifestations. The dominant drivers of pathophysiology are hyperandrogenism and insulin resistance. Both conditions are related to cardiometabolic risk factors, such as obesity, hypertension, dyslipidaemia, hyperglycaemia, type 2 and gestational
-
Neutrophil-Lymphocyte Ratio and Red Blood Cell Distribution Width in Patients with Atrial Fibrillation and Rheumatic Valve Disease Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-09-22 Rose Mary Ferreira Lisboa da Silva, Lucas Espindula Borges
The lifetime risk of developing atrial fibrillation (AF) is 1 in 3 adults, resulting in a prevalence of 2-4%. Rheumatic heart disease (RHD) is a frequent aetiology of valvular heart disease in lowand middle-income countries. Between 21% and 80% of patients with mitral valve disease, especially with stenosis, may have AF. Both these conditions, AF and RHD, present a state of persistent inflammation
-
MDMB-FUBINACA Influences Brain Angiogenesis and the Expression of VEGF, ANG-1, and ANG-2 Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-09-13 Laith AL-Eitan, Mishael Alkhawaldeh
Aim: This study aims to explore the impact of the synthetic cannabinoid methyl 2-(1-(4- fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-FUBINACA) on the angiogenesis process in human brain microvascular endothelial cells. Background: Synthetic cannabinoids (SCs) are substances that mimic the natural components found in the cannabis plant. SCs are considered prohibited substances
-
Aortic Intima-Media Thickness is Increased in Neonates of Mothers with Gestational Diabetes Mellitus: The Role of Thioredoxin-Interacting Protein as a Marker of Oxidative Stress Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-08-28 Pinelopi Triantafyllidou, Anna Papadopoulou, Eirini Thymara, Vassiliki Papaevangelou, George Mastorakos, Anastasios Papadimitriou, Sophia Kalantaridou, Constantine A. Stratakis, Efthymia Alexopoulou
Background: Offspring exposed in foetal life to gestational diabetes mellitus (GDM) are at increased risk for future metabolic diseases. Objective: To explore the prognostic role of abdominal aorta intima-media thickness (aIMT) in neonates exposed to GDM as a possible biomarker for later atherogenesis and its possible correlation with thioredoxin- interacting protein (TXNIP), a protein involved in
-
The Gulf Achievement of Cholesterol Targets in Out-Patients Study (GULF ACTION): Design, Rationale, and Preliminary Results Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-08-18 Hanan B Albackr, Khalid Al Waili, Wael Almahmeed, Mohammad Al Jarallah, Mohammad I Amin, Khalid Alrasadi, Mohammed A. Batais, Turky H. Almigbal, Ali Youssef, Mohammad Alghamdi, Mohammad Al Shehri, Islam Ahmad, Riham A. ElToukhy, Naji Kholaif, Abdulhalim J. Kinsara, Manal Al-kindi, Nooshin Barzargani, Magdy Hassan, Shamsa Al Suwaidi, Rajesh Rajan, Hani Altaradi, Khalid F Alhabib
Aim: To assess the current dyslipidemia management in the Arabian Gulf region by describing the demographics, study design, and preliminary results of out-patients who achieved low-density lipoprotein cholesterol (LDL-C) goals at the time of the survey. Background: The Arabian Gulf population is at high risk for atherosclerotic cardiovascular disease at younger ages. There is no up-to-date study regarding
-
Selenium, Selenoproteins and 10-year Cardiovascular Risk: Results from the ATTICA Study Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-08-10 Paraskevi Detopoulou, Sophia Letsiou, Tzortzis Nomikos, Alexandros Karagiannis, Spiros A. Pergantis, Christos Pitsavos, Demosthenes B. Panagiotakos, Smaragdi Antonopoulou
Background: Selenium (Se) is an essential trace element that is involved in several pathophysiological functions. The relationship of Se with cardiovascular disease remains inconclusive, especially regarding the role of different selenospecies. Objective: The present study assessed the levels of Se distribution in plasma selenoproteins, namely glutathione peroxidase 3 (GPx3), selenoprotein P (SelP)
-
Implementation and Importance of Cardiac Rehabilitation for Cardiac Patients in Saudi Arabia: A Systematic Review Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-08-09 Raheeq Hadi Ahmed, Bussma Ahmed Bugis
Objective: Cardiac rehabilitation (CR) has progressed over the years from a basic monitoring procedure for a safe return to physical activity to a multidisciplinary strategy that emphasizes patient education, specifically for designed exercise training, risk factor management, and the general health of cardiac patients. Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
-
Role of Brain Endothelin Receptor Type B (ETB) in the Regulation of Tyrosine Hydroxylase in the Olfactory Bulb of DOCA-Salt Hypertensive Rats Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-08-09 Luis Cassinotti, María Guil, Liliana Bianciotti, Marcelo Vatta
Background: We previously reported that endothelins (ETs) regulate tyrosine hydroxylase (TH) activity and expression in the olfactory bulb (OB) of normotensive and hypertensive animals. Applying an ET receptor type A (ETA) antagonist to the brain suggested that endogenous ETs bind to ET receptor type B (ETB) to elicit effects. Objective: The aim of the present work was to evaluate the role of central
-
Aerobic Physical Exercise is Essential for Cardiac Autonomic Regulation in Hypertensive Patients Undergoing Chronic Treatment with Renin- Angiotensin System Inhibitors Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-07-03 Tábata de Paula Facioli, Stella Vieira Philbois, Jens Tank, Ada Clarice Gastaldi, Bruno Augusto Aguilar, Ana Catarine da Veiga Oliveira, Lucas Dalvit Ferreira, Hugo Celso Dutra de Souza
Background: Hypertension treatment with renin-angiotensin system inhibitors (RASi) presents contradictions about the recovery of damage in cardiovascular autonomic modulation characterized by reduced heart rate variability (HRV) and increased blood pressure variability (BPV). Conversely, the association of RASi with physical training can influence achievements in cardiovascular autonomic modulation
-
Clinical Features, Socioeconomic Status, Management, and Outcomes of Acute Heart Failure: PEACE MENA Registry Phase I Results Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-06-26 Hanan AlBackr, Khalid F. Alhabib, Kadhim Sulaiman, Amal Jamee, Mohamed Sobhy, Salim Benkhedda, Sobhi Dada, Ayman Hammoudeh, Habib Gamra, Ahmed Al-Motarreb, Fahad Alkindi, Mohammad I Amin, Magdi G. Yousif, Hasan A. Farhan, Nadia Fellat, Wael Almahmeed, Mohammad Al Jarallah, Prashanth Panduranga, Magdy Abdelhamid, Ihab Ghaly, Dahlia Djermane, Ahcene Chibane, Hadi Skouri, Mohamad Jarrah, Hassen Amor,
Introduction: PEACE MENA (Program for the Evaluation and Management of Cardiac Events in the Middle East and North Africa) is a prospective registry in Arab countries for in-patients with acute myocardial infarction (AMI) or acute heart failure (AHF). Here, we report the baseline characteristics and outcomes of in-patients with AHF who were enrolled during the first 14 months of the recruitment phase
-
Drugs as Possible Triggers of Takotsubo Cardiomyopathy- Update 2022: Systematic Review Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-06-22 Valentina Lopera, Jaime Andrés Pereañez, Pedro Jose Amariles
Background: A list of drugs that can induce takotsubo cardiomyopathy (TCM) was published in 2011 and 2016. The aim of the present review was to update this list. Methods: Similar to the 2011 and 2016 reviews, from April 2015 to May 2022 case reports of druginduced TCM were identified by a comprehensive search in Medline/PubMed database. The search terms were: takotsubo cardiomyopathy, tako-tsubo cardiomyopathy
-
Effects of Cilostazol on the Myocardium in an Obese Wistar Rat Model of Ischemia-Reperfusion Injury Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-06-06 Tolga Demir, Mazlum Sahin, Fatma Tugba Ilal Mert, Fatma Sarac
Objectives: This study aims to determine the protective effect of cilostazol on myocardium in obese Wistar rats with induced ischemia-reperfusion injury (IRI). Methods: Four groups with 10 Wistar rats were included: 1] Sham Group: IRI was not established in normal weight-Wistar rats. 2] Control Group: IRI but no cilostazol in normal weight-Wistar rats. 3] Cilostazol in normal weight-Wistar rats: IRI
-
Cardiovascular Protection of Aspirin in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-06-01 Rong Gong, Ting Chen, Yunlei Deng
Purpose: This is to evaluate aspirin's cardiovascular (CV) protective effect in chronic kidney disease (CKD) patients. Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science (up to December 2022) for randomized controlled trials (RCTs) and observational studies comparing aspirin with placebo in CKD patients for the prevention of CV disease (CVD). Efficacy outcomes included CVD, heart
-
Hypertension-Mediated Organ Damage In Young Patients With First-Diagnosed And Never Treated Systolic Hypertension Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-05-31 Dimitris Benas, Helen Triantafyllidi, Dionyssia Birmpa, Anastasia Fambri, Antonios Schoinas, Ioannis Thymis, Gavriela Kostelli, Ignatios Ikonomidis
Objective: Early onset of untreated arterial hypertension is associated with an increased risk for cardiovascular (CV) diseases. The evaluation of hypertension-mediated organ damage (HMOD) helps estimating CV risk. We investigated the incidence of HMOD in young first, diagnosed and nevertreated patients with systolic arterial hypertension (SH) to identify high CV-risk patients based on the presence
-
The Prospect of Genomic, Transcriptomic, Epigenetic and Metabolomic Biomarkers for The Personalized Prevention of Type 2 Diabetes and Cardiovascular Diseases Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-05-31 Aleksandra Zeljkovic, Marija Mihajlovic, Sanja Vujcic, Azra Guzonjic, Jelena Munjas, Aleksandra Stefanovic, Jelena Kotur-Stevuljevic, Manfredi Rizzo, Natasa Bogavac-Stanojevic, Jelena Gagic, Jelena Kostadinovic, Jelena Vekic
Cardiometabolic diseases, such as type 2 diabetes mellitus (DM) and cardiovascular disease (CVD), are a great health concern. The strategies aimed to increase awareness and prevention, in conjunction with timely diagnosis and optimal management of these conditions, represent the main lines of action to improve life expectancy and quality. In recent years, the introduction of innovative therapies for
-
The cGAS-STING Pathway: A Ubiquitous Checkpoint Perturbing Myocardial Attributes Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-05-19 Xueqi wan, Jinfan Tian, Peng Hao, Jing Zhang, Yuquan Zhou, Changjiang Ge, Xiantao Song
As an innate immune route of defense against microbial infringement, cyclic guanosine monophosphate (GMP)–adenosine monophosphate (AMP) synthase (cGAS)- stimulator of interferon genes (STING) signaling does not simply participate in amplifying inflammatory responses via releasing type-I interferon (IFN) or enhance the expression of pro-inflammatory genes, but also interplays with multifarious pathophysiological
-
STOPP/START Anti-aggregation and Anticoagulation Alerts in Atrial Fibrillation Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-05-04 Francesco Salis, Antonella Palimodde, Samuele Rundeddu, Antonella Mandas
Background: Atrial Fibrillation (AF) is common in the elderly. A key component of AF management is Oral Anticoagulant Therapy (OAT), consisting of Vitamin K Antagonists (VKAs) or Direct Oral Anticoagulants (DOACs). The aim of the present study is to check, using STOPP (Screening Tool of Older Persons’ Prescriptions)/START (Screening Tool to Alert to Right Treatment) Criteria, if such drugs are potentially
-
Features of a Balanced Healthy Diet with Cardiovascular and Other Benefits Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-05-03 Antonis A. Manolis, Theodora A. Manolis, Helen Melita, Antonis S. Manolis
Background: Cardiovascular (CV) disease (CVD) remains the leading cause of death globally. Besides lack of exercise, obesity, smoking, and other risk factors, poor nutrition and unhealthy/ unbalanced diets play an important role in CVD. Objective: This review examined data on all issues of the CV-health benefits of a balanced diet, with tabulation of nutritional data and health-authority recommendations
-
Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-04-14 Jin Xu, Liyuan Zhu, Yingying Xie, Miao Zhang, Zixi Xiao, Rongkai Su, Tie Wen, Ling Liu
Background: Hypertriglyceridemia, is commonly found in patients with diabetes. Xuezhikang, an extract of red yeast rice, is effective in reducing cardiovascular events in Chinese patients with diabetes and coronary heart disease (CHD). Xuezhikang has been reported to significantly decrease the level of triglycerides (TG), a potential causal risk factor for myocardial infarction. On the basis of a similar
-
Protective Role of Cytochrome C Oxidase 5A (COX5A) against Mitochondrial Disorder and Oxidative Stress in VSMC Phenotypic Modulation and Neointima Formation Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-04-07 Haijing Guan, Jingwen Sun, Xiuying Liang, Wenjuan Yao
Background: The pathological role of cytochrome c oxidase 5A (COX5A) in vascular neointima formation remains unknown. Aim: This study aims to investigate the role of COX5A on platelet-derived growth factor BB (PDGFBB)- mediated smooth muscle phenotypic modulation and neointima formation and clarify the molecular mechanisms behind this effect. Methods: For in vitro assays, human aortic vascular smooth
-
“Renalism” with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-04-07 Hussein Al Sudani, Samir Shah, Kevin Bryan Lo, Hani Essa, Ammaar Wattoo, Lucas Angelim, Sophia Brousas, Isabel Whybrow-Huppatz, Shaitalya Vellanki, Rajiv Sankaranarayanan, Janani Rangaswami
Introduction: Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRA) reduce mortality and hospitalizations in heart failure with reduced ejection fraction (HFrEF) but their use is limited in advanced chronic kidney disease (CKD). Methods: We carried out a systematic review
-
Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-02-27 Shuangbo Liu, Janine Eckstein, Anna Lam, Asim N. Cheema
Background: Evidence regarding using acetylsalicylic acid (aspirin) for the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM) is inconsistent. Therefore, we performed a meta-analysis. Methods: A literature search was performed (January 1990 to February 2022) and publications meeting the inclusion criteria were reviewed, and a meta-analysis was performed using RevMan software
-
Significance of Beta-Blocker in Patients with Hypertensive Left Ventricular Hypertrophy and Myocardial Ischemia Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-02-24 Goran Koracevic, Slađana Mićić, Milovan Stojanovic, Nenad Bozinovic, Dragan Simic, Dragan Lović, Nebojsa Krstic, Ružica Janković Tomašević
Background: Arterial Hypertension (HTN) is a key risk factor for left ventricular hypertrophy (LVH) and a cause of ischemic heart disease (IHD). The association between myocardial ischemia and HTN LVH is strong because myocardial ischemia can occur in HTN LVH even in the absence of significant stenoses of epicardial coronary arteries. Objective: To analyze pathophysiological characteristics/co-morbidities
-
Preliminary Study of the Distinctive Mechanism of Shenqi Compound in Treating Rats with Type 2 Diabetes Mellitus by Comparing with Metformin Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-02-20 Xiaoxu Fu, Xiujuan Zhou, Ya Liu, Yuanhong Lei, Hongyan Xie, Yulin Leng, Hong Gao, Chunguang Xie
Background: In China, traditional Chinese medicine (TCM) has been used to treat type 2 diabetes mellitus (T2DM) for centuries. Methods: To investigate how the TCM ShenQi (SQC) formulation differs from metformin, four rat groups, including control, model, T2DM rats treated using SQC (SQC group), and T2DM rats treated using metformin (Met group), were constructed. The differentially expressed genes (DEGs)
-
Twin Anemia-Polycythemia Sequence (TAPS): From Basic Research to Clinical Practice Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-02-16 Joana da Silva Rocha, Luís Guedes-Martins, Ana Cunha
Twin pregnancy is associated with an increased risk of perinatal and maternal complications, and early establishment of the chorionicity type defines this risk. In monochorionic (MC) pregnancies, the fetuses share the same placental mass and exhibit vascular anastomoses crossing the intertwin membrane, and the combination and pattern of anastomoses determine the primary clinical picture and occurrence
-
Clinical and Laboratory Evaluation of Acute Pericarditis Associated with Antinuclear Antibodies Positivity Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-02-16 Ali Doğan Dursun, Ersin Saricam, Hakan Erdem, Gulcin Turkmen Sariyildiz, Esref Umut Ozyer, Engin Bozkurt, Erdogan Ilkay, Ömer Faruk Cantekin
Background: Up to 30% of patients with acute pericarditis develop recurrent pericarditis. Acute pericarditis may be a manifestation of an underlying systemic autoimmune disease. Therefore, we evaluated the characteristics of patients with acute pericarditis according to antinuclear antibodies (ANA) positivity/negativity. Methods: Participants with acute pericarditis and negative ANA (n=29), recurrent
-
The Emerging Role of CircRNAs in Atherosclerosis Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-02-07 Jing Yang, Shuling Rong
Cardiovascular diseases (CVDs) based on atherosclerosis remain the main reason for death in Western countries and China. Cardiovascular research has demonstrated that its pathogenesis is closely associated with endothelial cell (EC) injury, the phenotypic transformation of vascular smooth muscle cells (VSMCs), and the abnormal biological behaviour of macrophages. In recent years, circular RNAs (circRNAs)
-
Effects of Exercise on Vascular Toxicity Associated with Breast Cancer Treatment: A Narrative Review Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2023-01-18 Marina L.D. Pera, Guilherme F. Speretta
Breast cancer is the most common cancer among women worldwide, and its incidence is linearly associated with age. The development of cancer treatments has changed the prognosis of this disease. Despite effective treatments, cardiovascular complications in middle-aged and older women have become challenging. Physical exercise is a powerful tool to prevent senescence symptoms and diseases, besides being
-
Non-alcoholic Fatty Liver Disease in Children Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2022-12-19 Emir Muzurović, Stergios A. Polyzos, Dimitri P. Mikhailidis, Sanja Borozan, Dušanka Novosel, Oleg Cmiljanić, Nataša Kadić, Christos S. Mantzoros
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the paediatric age. The growing prevalence of NAFLD and its advanced phenotype, non-alcoholic steatohepatitis (NASH), in children and adolescents parallels similar trends in obesity and type 2 diabetes mellitus. This trend may have serious long-term implications, including hepatic and extra-hepatic morbidity and mortality
-
The Prognostic Value of Previous Coronary Stent Implantation in Patients Undergoing Myocardial Revascularization Surgery Curr. Vasc. Pharmacol. (IF 4.5) Pub Date : 2022-11-02 Jose Manuel Villaescusa-Catalan, Jorge Rodríguez-Capitán, Cristina Isabel Sanz-Sánchez, Gemma Sánchez-Espín, José Luis Guerrero-Orriach, Francisco Javier Pavón Morón, Lourdes Fernández-Romero, José María Melero-Tejedor, Miguel Such-Martínez, Carlos Porras-Martín, Manuel Jiménez-Navarro
Background: Currently, studies are underway to determine whether coronary stent implantation with percutaneous transluminal coronary angioplasty before a coronary artery bypass graft (CABG) influences the prognosis of surgery. This study aimed to assess the need for future revascularisation or all-cause mortality as a composite endpoint after CABG surgery among patients with previous stent implantation